Lithostathine, a pancreatic secretory protein originally purified from pancreatic stones,' has been recently shown to inhibit nucleation and crystal growth of calcium carbonate. 2 Thus, lithostathine is currently postulated to prevent calcic lithogenesis in the normally supersaturated pancreatic juice. At least four isoforms of lithostathine (lithostathine secretory S2-5), corresponding to various degrees of glycosylation of the same polypeptide backbone, are secreted by the pancreas.3 4 Mild trypsinisation of the native protein produces a cleavage of the polypeptide in position 11-12,5 thus originating two fragments (lithostathine hydrolysed forms): the N-terminal hydrophilic undecapeptide (lithostathine H1), which bears the carbohydrate moiety and retains the inhibitory properties on the crystal growth, and a biologically inactive2 and poorly soluble6 7 sequence of 133 aminoacids (lithostathine H2).
The occurrence of an impaired secretion of lithostathine in patients with calcifying chronic pancreatitis (CP) is controversial. Decreased concentrations of lithostathine in the pancreatic juice and of lithostathine-mRNA in the pancreas of CP patients were first reported. 8 9 Subsequent studies with immunoassay, however, failed to confirm a difference in juice concentrations between patients and controls. 10 11 A different specificity of the antibodies for the various lithostathine-isoforms is thought to account for these conflicting results.12 13 The primary aim of this investigation was to develop a fast protein liquid chromatography (FPLC) technique capable of purifying and measuring secretory lithostathine in human pure pancreatic juice by a non-immunological method. The comparison of juice concentrations of lithostathine in patients with CP and in controls was also planned.
Methods

IMMUNOPURIFIED LITHOSTATHINE
Pure lithostathine was a gift from Dr J P Bernard from the U-315 INSERM laboratory of Marseille, where the protein had been purified from pooled pancreatic juices by an affinity column bearing an anti-lithostathine polyclonal antibody, as previously described. 3 The purity and the concentration of the peptide preparation were tested by aminoacid analysis on a Beckman System 6300 analyser (Beckman Instruments, San Ramon, CA).
Three samples of immunopurified lithostathine, differently treated after immunopurification, were tested by FPLC. The first sample had been collected in a mixture of protease inhibitors (diisopropylfluorophosphate 1 mM, 3-phenylpropionate 2 mM, benzoylarginine 0.5 mM, benzamidine 5 mM), and then freeze dried and stored at -20°C. A second sample had been similarly collected but stored as a solution, which had been thawed several times before FPLC analysis. A third sample had been collected and stored in the absence of protease inhibitors.
PANCREATIC JUICE COLLECTION
Pure pancreatic juice was collected by selective endoscopic cannulation of the major pancreatic duct, in the three minutes after the intravenous injection of 1 U/kg of secretin (Sekretolin Diagnosticum, Hoechst, Mannheim). At time of endoscopy, patients were treated with intravenous injection of diazepam (10 mg) and hyoscine butylbromure (40 mg). No visual evidence of bile contamination was present in the pancreatic juice. The injection of contrast medium into the pancreatic duct for diagnostic purposes always followed the juice collection.
Juice samples were collected in iced tubes containing diisopropyl-fluorophosphate at a final concentration of 1 mM. Each sample was then centrifuged at 750 g at 40C for three minutes; supernatants were aliquoted and their total protein content was measured.14 Before storage at -800C, an aliquot of each juice sample was tested for chymotryptic activity (titrimetric method; N-alpha-p-tosyl-l-arginine methyl ester, Sigma, USA, as a substrate). Only samples totally devoid of chymotryptic activity were stored for the purposes of this study. 
JUICE
The reproducibility of the FPLC chromatograms (overall area of eluted peaks and relative areas of each peak) was first assessed by running six times the same sample of pancreatic juice. The ratio between the area of the peaks coeluting with the S isoforms of immunopurified lithostathine and the overall area of proteic eluates at FPLC was then determined for each sample.
A reference curve plotting the cumulative area of the S lithostathine peaks versus known amounts of immunopurified protein (from 50 pg to 50 pug) applied to the column, was also constructed. The recovery of lithostathine in the juice assay was tested by adding various amounts of immunopurified S lithostathine (12.5, 25 , and 50 Kug) to a sample of pancreatic juice.
Absolute concentrations of juice S lithostathine were calculated by multiplying the S lithostathine/total protein ratio for the total protein content of the juice sample or by reference to the standard curve. patients in whom a diagnostic endoscopic retrograde cholangiopancreatography (ERCP) had been requested. Juice devoid of any tryptic activity, however, was obtained only in 16 patients whose final diagnosis was CP in eight cases, acute recurrent pancreatitis in two, biliary lithiasis in two, chronic alcoholism without signs of pancreatitis in two, and irritable bowel syndrome in two cases. All patients gave their informed and written consent for the investigation.
In all cases the diagnosis of calcifying CP was based on clinical presentation and on typical abnormalities at ERCP.18 19 All CP patients were men (mean age 45 years, range -10 22-62). The aetiology of CP was alcoholic in five patients (ethanol intake >80 g/day) and idiopathic in three. In one patient with idiopathic CP associated to pancreas divisum, > ERCP excluded obstructive pancreatitis.
Radio-opaque calcifications of the pancreas -were reported only in four patients (three -.5°alcoholic and one idiopathic). (Fig 1 C) . 
FPLC OF JUICE SAMPLES
Fifteen peaks eluting between 1 and 55 minutes, were detected by ultraviolet absorption at FPLC of each juice sample (Fig 3 shows  the chromatogram from a control patient) . Peaks numbers 6 and 7 were found to coelute with S isoforms of immunopurified lithostathine.
The coefficient of variation of the total area of eluted peaks at six runs of the same juice sample was always lower than 5%. The overall area of ultraviolet peaks correlated with the protein content of the juice sample (r=0-99). The interassay variation of the relative areas of peaks numbers 6 and 7 was less than 3%. Figure 4 illustrates the SDS-PAGE pattern of the FPLC peaks eluted from a sample of pancreatic juice. The eluate of peak number 1 was characterised by multiple proteic bands, none of which were in the 15-20 region. Conversely, most of the other FPLC fractions were found to contain a single protein. Peak number 6 was characterised by a single electrophoretic spot of 18, whereas SDS-PAGE of peak number 7 resolved only a 16 band.
The Table shows Time (min) Figure 3 : FPLC chromatogram of a sample ofpancreatic juice from a control patient. The elution time is reported to the top ofeach of the 15 resolved peaks. The dashed peaks coeluted with the two major peaks of non-degradated pure lithostathine (see chromatogram in Fig 1A) . The At immunoblot with polyclonal lithostathine antibody, only eluates from peak number 6 and 7 showed reactive bands (Fig 5) . The Figure 7 shows the relative concentrations of juice S lithostathine (,ug/mg of total protein), as calculated by adding the values of the relative areas of peaks number 6 and 7. No overlap was seen between patients with CP and controls. Among CP patients, there was no correlation of S lithostathine juice concentrations with the presence of pancreatic calcifications, with the cause of pancreatitis, and with the severity of ERCP changes. Among controls, the lowest relative concentrations of S lithostathine were found in the two alcoholic patients without clinical and radiological evidence of pancreatic damage.
As the absolute juice concentrations of S lithostathine (,ug/ml) were calculated by the S lithostathine/total protein ratio or by reference to the standard curve (Fig 6) , a less than 10%
... Proteases are currently assumed to play an important part in the transformation of lithostathine from S to H isoforms. A trypsin like hydrolysis of the Arg-Ile bond in position 11-12 of the native protein has been shown in vitro.5 Consistently, the FPLC analysis of purified lithostathine showed minimal amounts of H isoforms when the immunopurificate had been preserved with protease inhibitors and stored as a lyophilised powder, whereas a significant transformation occurred under less strict conditions of storage (Fig 1) .
As the FPLC method was applied to the fractionation of pancreatic juice proteins, 15 peaks were resolved and characterised. Again, our first concern was to verify that lithostathine transformation did not occur during collection, storage, and FPLC of juice. In fact, the immunoblot revealed no 15 anti-lithostathine band in the non-fractionated juice samples, nor in their FPLC fractions (including peaks near coeluting with the H isoforms generated from immunopurified lithostathine). Actually, H isoforms, eluting at 40 minutes, were identified in juice samples excluded from this study because of tryptic activity (unpublished data). The post-FPLC recovery of intact proenzymes at SDS-PAGE provided additional evidence that enzymatic activation of the juice samples was adequately prevented through the entire analytical process. Another crucial point in the FPLC analysis of juice was the recovery of two definite peaks (peak numbers 6 and 7) perfectly corresponding to the peaks of secretory isoforms from immunopurified lithostathine and with identical patterns both at SDS-PAGE and at immunoblot (Figs 1 to 5) .
Once the FPLC of pancreatic proteins was qualitatively satisfactory, we focused on the possibility of measuring the concentration of secretory lithostathine in pancreatic juice. In fact, the excellent reproducibility of the n L. -computer assisted integration of the peak areas permitted the calculation of the per cent ratio of S lithostathine to total protein and then the relative concentration of juice S lithostathine. The accuracy of this determination was confirmed by the finding of nearly identical results when the S lithostathine concentrations were calculated by referring to a standard curve plotting the cumulative area of S lithostathine peaks versus known amounts of pure standard. This, together with the very good recovery of S lithostathine standard in pancreatic juice, permitted a full validation of the assay.
Our analytical results show that S isoforms of lithostathine account for no more than 5-6% of total secretory protein in subjects without pancreatic damage. In their first studies using radial immunodiffusion, De Caro and Multigner reported a higher ratio of about 1 5%.8 25 Subsequently, more refined immunoassays detected relative concentrations of lithostathine in the same range of our results. 1012
Previous data from immunoassays are much more controversial about the occurrence of decreased concentrations of lithostathine in juice of patients with CP. By using polyclonal antibodies, both Multigner and ProvansalCheylan found that the amount of lithostathine, relative to total secretory protein, was decreased in Cp.8 12 The finding of decreased juice concentrations of encoding mRNA,9 and then the finding of a reduced synthesis of lithostathine in these patients, supported those analytical results. The same French group could not, however, confirm the difference between CP patients and controls when antilithostathine monoclonal antibodies were used for the immunoassays.12 Later, Schmiegel et al found no difference between patients and controls by using a fluorometric immunoassay with a commercial monoclonal antibody that recognises only low molecular weight hydrolised isoforms. 1 To explain these discrepancies, a different affinity of monoclonal and polyclonal antibodies for the various lithostathine isoforms has been claimed. However, immunobinding studies of the single antibodies have not been made available. Therefore, the results of our non-immunological assay are particularly important as they finally confirm the association with CP of a decreased secretion of lithostathine and show the absence of overlapping values of juice lithostathine concentration in controls.
As to the implications of a decreased secretion of lithostathine in the pathogenesis of CP, our data do not permit final conclusions. The reduced juice concentration of the protein might play a primary part in the development of the disease or it might simply be an epiphenomenon. We did not find any correlation between the juice concentrations of lithostathine and the stage or the cause of the disease. Also Multigner et al, using an immunoassay in a larger series, found no difference in juice lithostathine between patients with alcoholic pancreatitis and those with hereditary or tropical CP, nor between patients with and those without calciflcations.8
This implies that the altered expression of the lithostathine gene is an early phenomenon in the course of the disease possibly predisposing to its development. Conversely, the finding of intermediate values of relative S lithostathine concentration in the pancreatic juice of alcoholic patients without pancreatitis shows that the alcohol consumption by itself can depress lithostathine secretion, regardless of the development of CP, suggesting a multifactorial pathogenesis of the disease. Alternatively, the comparatively low concentrations of lithostathine in alcoholic patients might reflect a preclinical stage of the disease.
The described non-immunological assay of secretory lithostathine, which is accurate and comparatively easy to perform, is expected to contribute to clarifying the role of this glycoprotein in the pathogenesis of CP. In particular, its application to longitudinal studies on subjects at risk of developing CP because of their drinking habits and to investigations on non-alcoholic patients with calcyfying CP is warranted. Conversely, a clinical use of the assay for diagnostic purposes seems to be greatly hampered by the tryptic activation often occurring during the endoscopic collection of pure pancreatic juice.
